ABBV vs HON: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Honeywell International Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-11.
AbbVie Inc. · Healthcare
$208.05
+4.5% upside to fair value
Grade C
High Quality
VS
Honeywell International Inc. · Industrials
$235.04
-9.9% upside to fair value
Med Conviction
Grade B
QuantHub Verdict
ABBV has more upside to fair value
(+4.5%).
ABBV trades at a lower forward P/E
(14.9x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
HON |
| Current Price |
$208.05 |
$235.04 |
| Fair Value Estimate |
$217.50 |
$211.73 |
| Upside to Fair Value |
+4.5%
|
-9.9%
|
| Market Cap |
$367.9B |
$149.4B |
| Forward P/E |
14.9x
|
22.3x
|
| EV / EBITDA |
16.7x
|
16.9x
|
| Price / Sales |
6.1x
|
4.0x
|
| Price / FCF |
20.9x
|
27.7x
|
| Revenue Growth YoY |
+8.6%
|
-2.7%
|
| Gross Margin |
83.7%
|
36.9%
|
| Operating Margin |
34.7%
|
17.7%
|
| Return on Equity |
-129.24%
|
33.28%
|
| Dividend Yield |
3.2% |
1.92% |
| FCF Yield |
4.78%
|
3.61%
|
| Analyst Consensus |
Buy
|
Buy
|
Investment Thesis
AbbVie is a leading diversified biopharmaceutical company navigating the post-Humira transition with strong momentum from Skyrizi and Rinvoq in immunology and continued growth in neuroscience. Full-year 2025 revenue reached $61.2 billion with a gross margin of 83.7% and operating margin of 34.7%, demonstrating operational strength despite the ongoing Humira erosion. Management guides to $67 billi…
Honeywell is a diversified industrial conglomerate in the final stages of a transformative three-way separation into Honeywell Aerospace, Solstice Advanced Materials, and a retained Automation entity, targeting Q3 2026 completion. The business generated 33% ROE and $5.4B in free cash flow on $37.4B revenue in FY2025, supported by a record $37B backlog with 23% organic order growth in Q4. At $235 …
Accumulation Zones
| Metric |
ABBV |
HON |
| Zone Low |
$163.13 |
$158.80 |
| Zone High |
$184.88 |
$179.97 |
| In Buy Zone? |
No
|
No
|